Optimizing Care for Cancer Survivors With Depression: Project 3

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed Show 4 more changesShow less
    • Final enrollment: 50 participants (planned 45)
    • Primary and study completion dates changed from estimate of Sep 21, 2026 to Sep 22, 2026
    • Eligibility criteria expanded, about 7 words
    • Site details revised
  2. Minor Primary and study completion pushed from Jun 23, 2026 to Sep 21, 2026v5
  3. Minor Primary and study completion dates: May 15, 2026 to Jun 23, 2026v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2025 to Aug 12, 2025
    • Site details revised
    v3
  5. Notable Start date: May 15, 2025 to Aug 1, 2025v2
  6. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to evaluate different depression treatment approaches among cancer survivors. A cancer survivor is defined as anyone who is living and has been diagnosed with cancer. Participants will be randomly assigned to either receive a mobile app for depression treatment, called "Moodivate", or to receive telehealth depression treatment sessions. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will receive depression treatment via telehealth. Participants that receive Moodivate may later be assigned to also receive depression treatment via telehealth based their response to the Moodivate app. Participants will be asked to either use the Moodivate app and/or receive depression treatment via telehealth for a period of 10 weeks. All participants will be asked to electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as general experiences using Moodivate and participating in this trial. Participation in this study will take about 24 weeks. Participation in this study may help improve options for emotional wellness for cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality.
Trial Details
NCT Number NCT06930729
Lead Sponsor Medical University of South Carolina
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)
Cancer, Depression
Related terms Depression, Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov